, Volume 70, Issue 1, pp 79–82 | Cite as

Flurazepam effects on methylphenidate-induced stereotyped behavior

  • Craig Risch
  • Daniel Kripke
  • David Janowsky
Original Investigations


The effects of flurazepam (0.0, 0.5, and 3.0 mg/kg) on methylphenidate-induced increases in stereotypy, gnawing, sniffing, and locomotion were evaluated in Swiss-Webster mice in daytime and night-time experiments. Methylphenidate (50 mg/kg) increased overall stereotypy and stereotyped gnawing behavior; two doses of methylphenidate (25 mg/kg and 50 mg/kg) increased locomotion and sniffing behavior. Flurazepam 3.0 mg/kg augmented methylphenidate-induced stereotyped gnawing behavior and stereotypy. Flurazepam significantly decreased locomotion and sniffing, but did not interact with methylphenidate's effects on locomotion and sniffing.

Key words

Methylphenidate Flurazepam Stereotyped behavior Dopamine Gnawing behavior Drug interaction 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Babbini M, Montanaro N, Strocchi P, Giaardi M (1971) Enhancement of amphetamine-induced stereotyped behavior by benzodiazepines. Eur J Pharmacol 13:330–340Google Scholar
  2. Blackwell B (1973) Psychotropic drugs in use today: the role of diazepam in medical practice. J.A.M.A. 225:1637Google Scholar
  3. Chiueh C, Moore K (1975) Blockade by reserpine of methylphenidate induced release of brain dopamine. J Pharmacol Exp Ther 2:559–563Google Scholar
  4. Greenblatt DJ, Miller RR (1974) Rational use of psychotropic drugs I. Hypnotics. Am J Hosp Pharm 31:990–995Google Scholar
  5. Greenblatt DJ, Shader RI (1974) Benzodiazepines in clincial practice. Raven Press, New YorkGoogle Scholar
  6. Herman ZS (1967) Influence of some psychotropic and adrenergic blocking agents upon amphetamine stereotyped behavior in white rats. Psychopharmacologia 11:136–142Google Scholar
  7. Kales A, Kales JD, Scharf MB, Tan TL (1970) Hypnotics and altered sleep patterns: II. All night EEG studies of chloral hydrate, flurazepam, and methaqualone. Arch Gen. Psychiatry 23:219–225Google Scholar
  8. Kales A, Kales JD, Bixler EO, Scharf MB (1975) Effectiveness of hypnotic drugs with prolonged use: Flurazepam and pentobarbital. Clin Pharmacol Ther 18:356–363Google Scholar
  9. Koch-Weser J, Greenblatt DJ (1974) The archaic barbiturate hypnotics. N Engl J Med 291:790–791Google Scholar
  10. Lal S, Sourkes TL, Missala K (1974) The effect of certain tranquilizers, chlorpromazine metabolites and diethyldithiocarbamate on tissue amphetamine levels in the rat. Arch Int Pharmacodyn Ther 207:122–130Google Scholar
  11. Randall LO, Schallek W, Scheckel CL, Stefko PL, Banziger RF, Pool W, Moe RA (1969) Pharmacolgical studies of flurazepam hydrochloride (R 05-6901), a new psychotropic agent of the benzodiazepine class. Arch Int Pharmacodyn Ther 178:216–241Google Scholar
  12. Randrup A, Munkvad I (1965) Special antagonism of amphetamine-induced abnormal behavior. Psychopharmacologia 7:416–422Google Scholar
  13. Scheel-Kruger J (1971) Comparative studies of various amphetamine analogues demonstrating different interactions with the metabolism of the catecholamines in the brain. Eur J Pharmacol 24:47–59Google Scholar
  14. Sleeping Pills, Insomnia, and Medical Practice (1979) Institute of Medicine. National Academy of Sciences, Washington, D.C.Google Scholar
  15. Taylor KM, Laverty R (1969) The effect of chlordiazepoxide, diazepam, and nitrazepam on catecholamine metabolism in regions of the rat brain. Eur J Pharmacol 8:296–301Google Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • Craig Risch
    • 1
  • Daniel Kripke
    • 1
  • David Janowsky
    • 1
  1. 1.Department of Psychiatry (M-003)University of California at San Diego, Medical SchoolLa JollaUSA

Personalised recommendations